EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs

Shuang Dong, Xiaoyu Li, Qing Huang, Yuanxiang Li, Jinjiao Li, Xianmin Zhu, Chang Xue, Runzhi Chen, Yuan Zeng, Jingyi Wu, Yi Zhong, Sheng Hu

Drug Resistance Updates · 2025

DOI: 10.1016/j.drup.2025.101215 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2025. Verfasst von Shuang Dong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, Ch…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm, Immunotherapy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 322 Literaturangaben. Gefördert von: Natural Science Foundation of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the last two decades, advancements in deciphering the intricate interactions between oncology and immunity have fueled a meteoric rise in immunotherapy for non-small cell lung cancer, typified by an explosive growth of immune checkpoint inhibitors. However, resistance to immunotherapy remains inevitable. Herein we unravel the labyrinthine mechanisms of resistance to immunotherapy, characterized by their involvement of nearly all types of cells within the body, beyond the extrinsic cancer cells, and importantly, such cells are not only (inhibitory or excitatory, or both) signal recipients but also producers, acting in a context-dependent manner. At the molecular level, these mechanisms underlie genetic and epigenetic aberrations, which are regulated by or regulate various protein kinases, growth factors, and cytokines with inherently dynamic and spatially heterogeneous properties. Additionally, macroscopic factors such as nutrition, comorbidities, and the microbiome within and around organs or tumor cells are involved. Therefore, developing therapeutic strategies combined with distinct action informed by preclinical, clinical, and real-world evidence, such as radiotherapy, chemotherapy, targeted therapy, antibody-drug conjugates, oncolytic viruses, and cell-based therapies, may stand as a judicious reality, although the ideality is to overcome resistance point-by-point through a novel drug. Notably, we highlight a realignment of treatment aims, moving the primary focus from eliminating cancer cells -- such as through chemotherapy and radiotherapy -- to promoting immune modulation and underscore the value of regulating various components within the host macro- or micro-environment, as their effects, even if seemingly minimal, can cumulatively contribute to visible clinical benefit when applied in combination with ICIs. Lastly, this review also emphasizes the current hurdles scattered throughout preclinical and clinical studies, and explores evolving directions in the landscape of immunotherapy for NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsDrug Resistance, NeoplasmImmunotherapyImmune Checkpoint InhibitorsHumansTumor MicroenvironmentAnimals

Stichwörter der Autor:innen

Combination therapyImmunotherapyNon-small cell lung cancerResistance

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, China.
  • Pfizer Inc, Shanghai 200040, China.
  • Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, China. Electronic address: iriszhong@126.com.
  • Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, China. Electronic address: 2010ZL0008@hust.edu.cn.

Förderung

  • Natural Science Foundation of Hubei Province

Zitieren

APA

Dong, S., Li, X., Huang, Q., Li, Y., Li, J., Zhu, X., Xue, C., Chen, R., Zeng, Y., Wu, J., Zhong, Y., & Hu, S. (2025). Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101215

Vancouver

Dong S, Li X, Huang Q, Li Y, Li J, Zhu X, et al. Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs. Drug Resistance Updates. 2025. doi:10.1016/j.drup.2025.101215

BibTeX
@article{Dong2025,
  author = {Dong, Shuang and Li, Xiaoyu and Huang, Qing and Li, Yuanxiang and Li, Jinjiao and Zhu, Xianmin and Xue, Chang and Chen, Runzhi and Zeng, Yuan and Wu, Jingyi and Zhong, Yi and Hu, Sheng},
  title = {Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs},
  journal = {Drug Resistance Updates},
  year = {2025},
  doi = {10.1016/j.drup.2025.101215}
}
Kostenlos starten →